David Pacitti Acquires Shares in OBIO
David Pacitti purchased 17,327 shares of OBIO, reflecting insider confidence.
Key Points
- David Pacitti bought 17,327 shares of OBIO on June 23, 2026, showing insider confidence.
- OBIO shares traded at $3.98 on Friday, with institutions like Millennium Management increasing their stakes by 188.6%.
- Analysts like B. Riley Securities maintained a 'buy' rating with a $10 target, reflecting positive sentiment.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Pacitti, an insider at OBIO, bought 17,327 shares of the company on June 23, 2026. This transaction did not disclose the price per share or the total value but signifies a notable insider purchase.
Other Institutional Activity in OBIO
RTW Investments, LP held steady with 8,306,063 shares valued at about $35.3 million. Perceptive Advisors LLC trimmed its stake by 89,350 shares, leaving it with 5,037,906 shares worth approximately $21.4 million, a 1.7% decrease. Vanguard Capital Management LLC opened a new position with 2,204,319 shares valued at around $9.4 million. Propel Bio Management, LLC also initiated a stake with 896,701 shares, valued at about $3.8 million. Millennium Management LLC increased its holdings by 459,070 shares to 702,543 shares, valued at nearly $3 million, marking a 188.6% increase.
Orchestra BioMed Holdings, Inc. Stock Down 23.2%
Shares of OBIO traded near $3.98 on Friday. The stock's recent activity reflects various institutional movements and insider transactions, with a focus on its potential growth in the market.
$OBIO stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Orchestra BioMed Holdings, Inc.
On June 23, 2026, David Pacitti acquired 17,327 shares. On June 24, 2026, several insiders, including Chris Cleary, John Prosper Mack, Eric Fain, and Pacitti himself, sold shares in smaller quantities. Jason Aryeh bought 42,553 shares on June 23, 2026.
Analysts Set New Price Targets
On May 19, 2026, B. Riley Securities maintained a 'buy' rating with a $10 price target for OBIO. Similarly, HC Wainwright & Co. reiterated their 'buy' rating with a $10 target on May 14, 2026. Barclays maintained a 'buy' rating with a $13 target on May 13, 2026, and Chardan Capital held a 'buy' rating with a $20 target on March 12, 2026.
Bottom Line
David Pacitti's purchase of OBIO shares suggests insider confidence in the company's performance. Institutional and insider movements provide a glimpse into the stock's potential, though these transactions are not current positions. Analyst ratings remain positive, with several firms maintaining 'buy' ratings and setting varied price targets, indicating continued interest in OBIO.
Get Orchestra BioMed Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.